Biogen/$BIIB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Biogen
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
Ticker
$BIIB
Sector
Primary listing
Employees
7,500
Headquarters
Website
Biogen Metrics
BasicAdvanced
$28bn
20.76
$9.30
0.19
-
Price and volume
Market cap
$28bn
Beta
0.19
52-week high
$205.97
52-week low
$121.05
Average daily volume
1.3m
Financial strength
Current ratio
3.065
Quick ratio
2.025
Long term debt to equity
35.181
Total debt to equity
35.181
Interest coverage (TTM)
9.87%
Profitability
EBITDA (TTM)
3,581.8
Gross margin (TTM)
78.72%
Net profit margin (TTM)
13.81%
Operating margin (TTM)
27.32%
Effective tax rate (TTM)
15.47%
Revenue per employee (TTM)
$1,320,000
Management effectiveness
Return on assets (TTM)
5.90%
Return on equity (TTM)
7.70%
Valuation
Price to earnings (TTM)
20.756
Price to revenue (TTM)
2.85
Price to book
1.53
Price to tangible book (TTM)
9.16
Price to free cash flow (TTM)
12.226
Free cash flow yield (TTM)
8.18%
Free cash flow per share (TTM)
15.781
Growth
Revenue change (TTM)
1.23%
Earnings per share change (TTM)
-8.10%
3-year revenue growth (CAGR)
-0.55%
10-year revenue growth (CAGR)
-0.95%
3-year earnings per share growth (CAGR)
-24.42%
10-year earnings per share growth (CAGR)
-5.44%
What the Analysts think about Biogen
Analyst ratings (Buy, Hold, Sell) for Biogen stock.
Biogen Financial Performance
Revenues and expenses
Biogen Earnings Performance
Company profitability
Biogen News
AllArticlesVideos
Investigation Alert: Biogen Inc. (BIIB) Under Scrutiny - Contact Levi & Korsinsky for Details
Newsfile Corp·2 days ago
Biogen Conference: Lupus, Kidney Programs Take Center Stage in Immunology Push
MarketBeat·3 days ago
Biogen advances Alzheimer's drug to late-stage trial despite disappointing data
CNBC·3 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Biogen stock?
Biogen (BIIB) has a market cap of $28B as of May 18, 2026.
What is the P/E ratio for Biogen stock?
The price to earnings (P/E) ratio for Biogen (BIIB) stock is 20.76 as of May 18, 2026.
Does Biogen stock pay dividends?
No, Biogen (BIIB) stock does not pay dividends to its shareholders as of May 18, 2026.
When is the next Biogen dividend payment date?
Biogen (BIIB) stock does not pay dividends to its shareholders.
What is the beta indicator for Biogen?
Biogen (BIIB) has a beta rating of 0.19. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.